Novavax, Inc. (NASDAQ:NVAX) Shares Bought by Barclays PLC

Barclays PLC increased its position in Novavax, Inc. (NASDAQ:NVAX) by 73.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 709,579 shares of the biopharmaceutical company’s stock after buying an additional 301,627 shares during the quarter. Barclays PLC’s holdings in Novavax were worth $8,961,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Shah Capital Management increased its holdings in shares of Novavax by 19.0% in the second quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock valued at $122,322,000 after buying an additional 1,544,263 shares in the last quarter. State Street Corp grew its holdings in shares of Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after acquiring an additional 1,621,772 shares during the last quarter. Bank of Montreal Can raised its position in shares of Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock worth $32,643,000 after purchasing an additional 517,727 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of Novavax by 48.9% during the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after purchasing an additional 656,900 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Novavax by 16.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company’s stock valued at $16,741,000 after purchasing an additional 187,548 shares during the period. Institutional investors own 53.04% of the company’s stock.

Novavax Stock Performance

NVAX stock opened at $9.00 on Wednesday. The firm has a 50 day simple moving average of $9.45 and a 200 day simple moving average of $12.09. Novavax, Inc. has a 52 week low of $3.53 and a 52 week high of $23.86.

Novavax (NASDAQ:NVAX) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The company had revenue of $84.51 million for the quarter, compared to analyst estimates of $65.80 million. During the same period last year, the business earned ($1.26) EPS. The company’s quarterly revenue was down 54.8% on a year-over-year basis. On average, sell-side analysts forecast that Novavax, Inc. will post -1.44 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. Jefferies Financial Group cut their price target on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, October 16th. Finally, B. Riley reaffirmed a “buy” rating and issued a $26.00 price objective (up previously from $23.00) on shares of Novavax in a research note on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $17.83.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.